ASH 2018 | Role of FLT3 inhibitors as maintenance following transplant in AML

Mark Levis

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the role of FLT3 inhibitors as a maintenance therapy following transplant in acute myeloid leukemia (AML).

Share this video